Thursday, July 9, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Lixte Biotechnology, Inc.”

26 pharma patents match "Lixte Biotechnology, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 26
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 26 pharmaceutical patents matching "Lixte Biotechnology, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

26 results for “Lixte Biotechnology, Inc.” · 30,257 patents in full index Clear search

  1. US 12343342

    Methods for treating soft tissue sarcoma

    Lixte Biotechnology, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted

  2. US 11931354

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Lixte Biotechnology, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted

  3. US 11866444

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted

  4. US 11236102

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  5. US 10668062

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes

    Lixte Biotechnology, Inc. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted

  6. US 10618908

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted

  7. US 10532050

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Lixte Biotechnology, Inc. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted

  8. US 10434100

    Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

    Lixte Biotechnology, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  9. US 10413541

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders

    Lixte Biotechnology, Inc. · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted

  10. US 10399993

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Lixte Biotechnology, Inc. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted

  11. US 10364252

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  12. US 10149847

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes

    Lixte Biotechnology, Inc. · Granted Dec 11, 2018 · Expires Dec 6, 2038

    granted

  13. US 10023587

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Lixte Biotechnology, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  14. US 9994584

    Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid

    Lixte Biotechnology, Inc. · Granted Jun 12, 2018 · Expires Jun 7, 2038

    granted

  15. US 9988394

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Granted Jun 5, 2018 · Expires May 31, 2038

    granted

  16. US 9833450

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders

    Lixte Biotechnology, Inc. · Granted Dec 5, 2017 · Expires Nov 30, 2037

    granted

  17. US 9079917

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Lixte Biotechnology, Inc. · Granted Jul 14, 2015 · Expires Jul 9, 2035

    granted

  18. US 8822461

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Lixte Biotechnology, Inc. · Granted Sep 2, 2014 · Expires Aug 28, 2034

    granted

  19. US 8541458

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Lixte Biotechnology, Inc. · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted

  20. US 8455688

    HDAC inhibitors

    Lixte Biotechnology, Inc. · Granted Jun 4, 2013 · Expires May 30, 2033

    granted

  21. US 8426444

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Lixte Biotechnology, Inc. · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  22. US 8329719

    Neuroprotective agents for the prevention and treatment of neurodegenerative diseases

    Lixte Biotechnology, Inc. · Granted Dec 11, 2012 · Expires Dec 6, 2032

    granted

  23. US 8227473

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Lixte Biotechnology, Inc. · Granted Jul 24, 2012 · Expires Jul 19, 2032

    granted

  24. US 8143445

    HDAC inhibitors

    Lixte Biotechnology, Inc. · Granted Mar 27, 2012 · Expires Mar 22, 2032

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.